Treatment with liraglutide may improve markers of CVD reflected by reduced levels of apoB

Engelbrechtsen, Line; Lundgren, J; Wewer Albrechtsen, Nicolai Jacob; Mahendran, Yuvaraj; Iepsen, Eva Pers Winning; Finocchietto, P.; Jonsson, Anna Elisabet; Madsbad, Sten; Holst, Jens Juul; Vestergaard, Henrik; Hansen, T.; Torekov, Signe Sørensen

Published in:
Obesity Science & Practice

DOI:
10.1002/osp4.133

Publication date:
2017

Document version
Publisher's PDF, also known as Version of record

Document license:
CC BY

Citation for published version (APA):
Treatment with liraglutide may improve markers of CVD reflected by reduced levels of apoB

L. Engelbrechtsen1,3†, J. Lundgren1,2†, N. J. Wewer Albrechtsen1,2, Y. Mahendran1,3, E. W. Iepsen1,2,3, P. Finocchietto1, A. E. Jonsson1, S. Madsbad4, J. J. Holst1,2, H. Vestergaard1, T. Hansen1 and S. S. Torekov1,2

1NNF Center for Basic Metabolic Research, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; 2Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark; 3The Danish Diabetes Academy, Odense, Denmark; 4Department of Endocrinology, Hvidovre Hospital, University of Copenhagen, Hvidovre, Denmark;

Received 15 May 2017; revised 24 August 2017; accepted 28 August 2017

Address for correspondence: Associate Professor SS Torekov, NNF Center for Basic Metabolic Research and Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Blegdamsvej 3B, 2200 Copenhagen, Denmark. E-mail: torekov@sund.ku.dk

†Contributed equally to the preparation of the manuscript.

Summary

Background
Dislipidaemia and increased levels of apolipoprotein B (apoB) in individuals with obesity are risk factors for development of cardiovascular disease (CVD). The aim of this study was to investigate the effect of weight loss and weight maintenance with or without liraglutide treatment on plasma lipid profiles and apoB.

Methods
Fifty-eight individuals with obesity (body mass index 34.5 ± 3.0 kg/m² [mean ± SD]) were included in this study. After 8 weeks on a very low-calorie diet (800 kcal/day), participants were randomized to weight maintenance with meal replacements with or without liraglutide (1.2 mg daily) for 1 year. Plasma samples from before and after weight loss and after 1 year of weight maintenance were subjected to nuclear magnetic resonance-based lipidomics analysis.

Results
After an 8-week low-calorie diet, study participants lost 12.0 ± 2.9 kg (mean ± SD) of their body weight, which was reflected in their lipid profiles (80 out of 124 lipids changed significantly), including reduced levels of apoB, total cholesterol, free cholesterol, remnant cholesterol, triglycerides, low-density lipoprotein and very low-density lipoprotein subclasses. After 1 year of maintained weight loss, the majority of the lipids had returned to pre-weight loss levels even though weight loss was successfully maintained in both groups. Interestingly, apoB levels remained low in the liraglutide treated group (apoB change: 0.03 ± 0.02 mmol/L, p = 0.4) in contrast to an increase in the control group (apoB change: 0.06 ± 0.07 mmol/L, p = 0.02).

Conclusion
An 8-week low-calorie diet, in individuals with obesity, reduced plasma levels of lipids and the atherogenic marker apoB. After 1 year of weight maintenance, only study participants treated with liraglutide maintained reduced levels of apoB, despite similar body weight maintenance. Treatment with liraglutide may therefore reduce apoB levels and thus reflect lower CVD risk. Including apoB measurements in clinical practice when monitoring patients with dislipidemia or CVD might prove to be useful.

Keywords: apoB, liraglutide, metabolomics, weight loss.
Levels of apoB have thus been suggested to be a superior predictor of CVD compared with levels of LDL because of the 1:1 ratio of apoB molecules and number of atherogenic lipoprotein particles (9–12). Measurement of apoB levels therefore provides information about all the atherogenic lipoproteins (very-LDL [VLDL], LDL and IDL) whereas measurement of only LDL levels does not account for VLDL and IDL levels. Individuals with obesity, metabolic syndrome and/or type 2 diabetes (T2D) frequently have increased levels of apoB despite relatively more normal LDL concentrations (13,14). Furthermore, these patient groups also have a two-fold to fourfold increased risk of CVD (15–17). An increased concentration of apoB and thus an increased amount of apoB-containing lipoproteins (VLDL, IDL and LDL) may trigger the process of atherosclerosis (10). Additionally, elevated levels of apoB have been linked with structural vascular changes including enlarged carotid intima-media thickness and increased arterial stiffness (18), all of which are risk factors of cardiovascular morbidity and mortality (18).

The glucagon-like peptide-1 receptor agonist (GLP-1RA) liraglutide, used in the treatment of T2D (19,20), has been approved for weight loss management in individuals with obesity (21) as it, together with low-calorie diet, induces a metabolically relevant sustained weight loss (~8–10 kg) by inhibiting appetite (22,23). Furthermore, treatment with liraglutide decreases cardiovascular mortality in individuals with T2D (the recent published LEADER study (26)); however, the underlying mechanism remains unknown. Interestingly, GLP-1 has been suggested to act as a regulator of intestinal lipid absorption through downregulation of apoB48 (24–26), but neither the effect of long-term GLP-1RA treatment on lipid metabolism nor its effect on the plasma levels of apoB in weight-reduced non-diabetic individuals with obesity have been evaluated.

Thus, we hypothesized that liraglutide may improve the atherogenic risk profile by reducing plasma concentrations of apoB. To test this, we used a nuclear magnetic resonance (NMR) spectroscopy-based metabolomics to delineate the potential effects of liraglutide on lipid fractions in humans using plasma samples from a previous randomized controlled clinical trial of 58 non-diabetic individuals with obesity (27). This investigation may thus aid to the understanding of one of the mechanisms behind the reduced risk of CVD with GLP-1RA treatment observed with liraglutide (28).

Method

Study participants

Fifty-eight glucose-tolerant individuals with obesity were enrolled in this previously described randomized controlled trial (27). Participants were aged between 18 and 65 years (45.9 ± 1.5 years) and had a mean body mass index of 34.4 kg/m² (range 30.0–39.9 kg/m²). Individuals were excluded from entering the study if they suffered from any acute or chronic diseases. Fifty-two participants completed the 8-week weight loss intervention period, and 42 individuals completed the 1-year study period (22 participants in the liraglutide group and 20 participants in the control group).

Weight loss programme

All participants were initially enrolled in a weight loss intervention programme for 8 weeks with the objective to lose at least 7.5% body weight. Intake of calories was based on a powdered formula mixture, which provided 810 kilocalories (3,402 kJ) per day. All products were provided by the Cambridge Diet (Cambridge Weight Plan). Standard recommendations for intake of essential amino acids, fatty acids, vitamins and minerals were met with this diet. Daily intake of protein was at least 43.2 g, and intake of essential fatty acids and linoleic acid was 3.0 and 0.4 g, respectively.

Randomization and weight maintenance programme

After 8 weeks on the low-calorie diet, the participants were randomized into two groups: one receiving a daily subcutaneous injection of liraglutide 1.2 mg daily (Flexpen device, Victoza, Novo Nordisk A/S, Bagsvaerd, Denmark) and another group serving as a control group. Both groups followed the Cambridge Weight Loss Maintenance Program along with calorie restriction (calorie need subtracted by 600 kcal) for the entire study period of one year. Furthermore, study participants received individual guidance on diet and exercise habits from a dietician following official Danish guidelines. If the participants experienced weight gain during the weight maintenance period, they were allowed to replace up to two meals per day with Cambridge Weight Plan products to ensure a stable weight. Both groups maintained the weight loss achieved in the initial weight loss programme (weight change in liraglutide group 0.49 ± 6.84 kg [mean ± SD] and in control group 2.23 ± 7.32 kg), and there was no significant weight difference between the groups after 1 year. However, the control group replaced on an average one meal per day with a low-calorie diet meal compared with no replacements in the liraglutide group (liraglutide group compared with control group, weight change in liraglutide group 0.49 ± 6.84 kg [mean ± SD] and in control group 2.23 ± 7.32 kg), and there was no significant weight difference between the groups after 1 year. However, the control group replaced on an average one meal per day with a low-calorie diet meal compared with no replacements in the liraglutide group (liraglutide group compared with control group, minus one meal per day (95% CI=−0.6 to −1), P<0.001) as previously described (27).
Blood samples after an overnight fasting were obtained before weight loss (screening), at baseline (after weight loss/randomization) and 1 year after baseline.

Metabolite quantification

Plasma samples were analysed using a high-throughput NMR-based platform (29). Lipids and their related metabolites (hereof lipid particles) in blood samples obtained at screening (before weight loss), baseline (after weight loss) and after 1 year of weight maintenance were detected. The high-throughput NMR platform (Nightingale Health Ltd, Helsinki, Finland) has previously been used in various epidemiological and genetic studies, and details of the experimental protocols, including sample preparation and spectroscopy, are described in references (29–33).

Statistical analyses

Statistical analyses were performed using R, version 3.1.3 (http://www.r-project.org).

All metabolites were log base 10-transformed prior to analysis to obtain normal distribution. Changes in metabolite concentrations within each group were analysed with Students Paired t tests. Changes in metabolite concentrations at each time point were compared between liraglutide and control group with a general linear model adjusted for sex, age and delta values for weight change or with an unpaired t-test. Data are shown as mean ± SD. To account for multiple testing, a false discovery rate (FDR) of 5% was used. P values < 0.026 were considered significant.

Lipid profile during weight loss intervention

The 12 kg weight loss was associated with a global shift in the composition of plasma lipids with significant changes in 80 out of the 124 measured lipid fractions (Table S1). Levels of both apoB (0.98 to 0.84 mmol/L, \( p = 1.8 \times 10^{-4} \)) and apoA1 (1.57 to 1.44 mmol/L, \( p = 1.1 \times 10^{-5} \)) decreased significantly. Furthermore, plasma concentration of total cholesterol (2.27 to 2.05 mmol/L, \( p = 1.5 \times 10^{-4} \)), ester cholesterol (3.18 to 2.76 mmol/L, \( p = 0.0002 \)), free cholesterol (1.34 to 1.24 mmol/L, \( p = 0.02 \)), remnant cholesterol (1.61 to 1.36 mmol/L, \( p = 0.0003 \)) and plasma triglycerides (1.46

Table 1 Demographic characteristics of study population

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Screening</th>
<th>Liraglutide group</th>
<th>Control group</th>
<th>p-value</th>
<th>Liraglutide group</th>
<th>Control group</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Inclusion</td>
<td>N = 58</td>
<td>17 (77%)</td>
<td>19 (95%)</td>
<td>0.19</td>
<td>17 (77%)</td>
<td>19 (95%)</td>
<td>0.19</td>
</tr>
<tr>
<td>Women</td>
<td>47 (81%)</td>
<td>17 (77%)</td>
<td>19 (95%)</td>
<td>0.19</td>
<td>17 (77%)</td>
<td>19 (95%)</td>
<td>0.19</td>
</tr>
<tr>
<td>Men</td>
<td>11 (19%)</td>
<td>5 (23%)</td>
<td>1 (5%)</td>
<td>0.19</td>
<td>5 (23%)</td>
<td>1 (5%)</td>
<td>0.19</td>
</tr>
<tr>
<td>Body weight (kg)</td>
<td>97.6 ± 11.8</td>
<td>88.1 ± 11.7</td>
<td>82.8 ± 7.5</td>
<td>0.09</td>
<td>87.85 ± 13.38</td>
<td>85.02 ± 10.4</td>
<td>0.45</td>
</tr>
<tr>
<td>BMI (kg m(^{-2}))</td>
<td>34.4 ± 2.8</td>
<td>31.3 ± 3.2</td>
<td>29.1 ± 2.0</td>
<td>0.01</td>
<td>31.15 ± 4.16</td>
<td>29.81 ± 3.11</td>
<td>0.25</td>
</tr>
<tr>
<td>Waist (cm)</td>
<td>109.2 ± 10.2</td>
<td>100 ± 9.7</td>
<td>95.3 ± 7.3</td>
<td>0.09</td>
<td>100.15 ± 14.28</td>
<td>96.35 ± 10.21</td>
<td>0.33</td>
</tr>
<tr>
<td>Waist:Hip ratio</td>
<td>0.92 ± 0.08</td>
<td>0.89 ± 0.08</td>
<td>0.86 ± 0.06</td>
<td>0.18</td>
<td>0.89 ± 0.10</td>
<td>0.85 ± 0.07</td>
<td>0.14</td>
</tr>
<tr>
<td>Total body fat %</td>
<td>41.9 ± 5.2</td>
<td>39.1 ± 6.3</td>
<td>39.5 ± 4.8</td>
<td>0.82</td>
<td>37.98 ± 6.91</td>
<td>38.5 ± 5.36</td>
<td>0.79</td>
</tr>
<tr>
<td>Delta value weight loss (screening to baseline and to one year)</td>
<td>-</td>
<td>-12.0 ± 3.2</td>
<td>-12.1 ± 2.5</td>
<td>0.91</td>
<td>2.23 ± 6.97</td>
<td>0.50 ± 6.69</td>
<td>0.42</td>
</tr>
</tbody>
</table>

Data are expressed as n (%) or mean ± SD.

BMI, body mass index.

Ethics

The study was approved by the Ethical Committee in Copenhagen (reference number: H-4-2010-134) and was performed in accordance with the Helsinki Declaration II. Participation in the trial was voluntary, and the participants could retract their consent to participate at any time. ClinicalTrials.gov Identifier: NCT02094183.

Results

Clinical characteristic of the study population

The two groups were comparable in terms of gender distribution (women/men ratio: liraglutide group: 85%/15%; control group: 92%/8%; \( p = 0.7 \)), body weight (liraglutide group: 98.6 ± 13.5 kg; controls: 96.8 ± 9.6 kg, \( p = 0.6 \)) and body fat percentage (liraglutide group: 41.4 ± 5.8; controls: 42.4 ± 4.7, \( p = 0.5 \)) (Table 1).
to 1.10 mmol/L, \( p = 0.009 \) were significantly reduced after the weight loss intervention. Also, significant changes in plasma concentrations of numerous subclasses of LDL, VLDL and HDL particles were observed (Figure 1A and B).

Liraglutide modifies levels of apolipoprotein B during 1 year of weight maintenance

Lipid estimates showed an overall increasing tendency, involving subclasses of HDL, LDL and VLDL particles. The increase in lipid fractions were seen in both groups (Figure 2A and B, Table S2).

All VLDL and LDL particles increased after 1 year of weight maintenance in the control group whereas, in contrast to, in the liraglutide-treated group, only L-VLDL and the content of triglycerides in S-VLDL increased (Table S2). For HDL-related particles, the control group showed increased plasma levels of HDL3-C, apoA1, S-, M-, L- and XL-HDL-C levels, and in the liraglutide group, plasma levels of HDL3-C, apoA1 and S- and M- HDL-C levels and decreases in HDL-TG content and density were observed (Figure 2, Table 2). In spite of an increase in HDL levels in both groups, the liraglutide group had significantly lower HDL3-C, S-, M- and XL-HDL levels than the control group (Figure 2, Table S2).
Furthermore, in the control group, an increase in total plasma cholesterol (+11%, \(p = 0.005\)), remnant cholesterol (+8%, \(p = 0.04\)), HDL-C (total cholesterol in HDL) (+17%, \(p = 0.009\)), total cholines (+12%, \(p = 1.6 \times 10^{-5}\)), ester cholesterol (+14%, \(p = 0.002\)), free cholesterol (+6%, \(p = 0.04\)), apoA1 (+12%, \(p = 4.9 \times 10^{-5}\)) and apoB (+7%, \(p = 0.025\)) was observed despite maintained weight loss. Similar results were observed in the liraglutide group with increases in cholesterol (+9%, \(p = 0.04\)), HDL-C (+8%, \(p = 0.01\)), total cholines (+8%, \(p = 0.004\)), ester cholesterol (+12%, \(p = 0.005\)) and apoA1 (+6%, \(p = 0.01\)). However, levels of remnant cholesterol \((p = 0.19)\), free cholesterol \((p = 0.99)\) and apoB \((p = 0.36)\) did not increase significantly in the liraglutide group (Figure 2, Table S2).

**Discussion**

Low-calorie diet-induced weight loss resulted in a global beneficial change in the plasma lipid profile of individuals with obesity. Furthermore, the cardio-beneficial reductions in apoB, LDL and triglycerides achieved by weight loss
were maintained by liraglutide treatment for 1 year. Thus, treatment with liraglutide maintained low levels of apoB, which may contribute to explain the reduced cardiovascular mortality reported in liraglutide-treated subjects with T2D (28). Changes in apoB levels were related to the parallel changes in the atherogenic lipids: LDL, VLDL and HDL. Despite a maintained weight loss, an overall tendency of increasing lipid particles towards pre-weight loss levels, mainly in the control group, indicating that the effect of a weight loss on lipid particles may only be acute and transient. We demonstrated that individuals with obesity treated with liraglutide after weight loss were able to sustain a weight loss-induced lowering of apoB levels in contrast to a control group. Interactions between GLP-1RA and weight loss were able to sustain a weight loss-induced lowering of apoB levels in contrast with liraglutide after weight loss. We demonstrated that individuals with obesity treated with liraglutide after weight loss were able to sustain a weight loss-induced lowering of apoB levels in contrast to a control group. Interactions between GLP-1RA and weight loss were able to sustain a weight loss-induced lowering of apoB levels in contrast with liraglutide after weight loss. Future studies, using a more biased approach to assess such changes in plasma levels of apoB48 and apoB100, are therefore needed. Plasma HDL particles are highly heterogeneous in their physicochemical properties, metabolism and biological activity, and the HDL response is variable and affected both by weight loss and by the type of dietary intervention (38,39). The effect of liraglutide on HDL levels has previously been described by others with diverging directions (40–44). The clinical relevance of lower HDL levels in liraglutide-treated individuals is not completely clarified. HDL-C is a known predictor of CVD; however, the causal link between HDL and atherosclerosis is still uncertain (45). In contrast, we observed lower HDL-C concentrations in liraglutide-treated individuals compared with

---

**Table 2 Biochemical measures in study population**

<table>
<thead>
<tr>
<th>Variable</th>
<th>Inclusion</th>
<th>Randomization</th>
<th>One year</th>
<th>p-value</th>
<th>Randomization</th>
<th>One year</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum Cholesterol (mmol/L)</td>
<td>4.53 ± 0.86</td>
<td>4.12 ± 0.58</td>
<td>4.42 ± 0.76</td>
<td>0.037</td>
<td>3.87 ± 0.75</td>
<td>4.40 ± 0.90</td>
<td>0.005</td>
</tr>
<tr>
<td>Triglycerides (mmol/L)</td>
<td>1.5 ± 0.84</td>
<td>1.12 ± 0.32</td>
<td>1.09 ± 0.44</td>
<td>0.395</td>
<td>0.99 ± 0.28</td>
<td>1.17 ± 0.84</td>
<td>0.519</td>
</tr>
<tr>
<td>VLDL-C (mmol/L)</td>
<td>0.90 ± 0.28</td>
<td>0.74 ± 0.17</td>
<td>0.77 ± 0.20</td>
<td>0.443</td>
<td>0.68 ± 0.17</td>
<td>0.76 ± 0.30</td>
<td>0.083</td>
</tr>
<tr>
<td>VLDL-D (nm)</td>
<td>35.96 ± 1.57</td>
<td>35.96 ± 0.85</td>
<td>36.20 ± 1.01</td>
<td>0.197</td>
<td>35.75 ± 0.72</td>
<td>36.19 ± 1.48</td>
<td>0.088</td>
</tr>
<tr>
<td>LDL-C (mmol/L)</td>
<td>1.57 ± 0.48</td>
<td>1.45 ± 0.33</td>
<td>1.57 ± 0.41</td>
<td>0.090</td>
<td>1.29 ± 0.38</td>
<td>1.46 ± 0.47</td>
<td>0.138</td>
</tr>
<tr>
<td>LDL-D (nm)</td>
<td>23.62 ± 0.12</td>
<td>23.73 ± 0.08</td>
<td>23.67 ± 0.07</td>
<td>0.0005</td>
<td>23.77 ± 0.10</td>
<td>23.67 ± 0.11</td>
<td>0.0004</td>
</tr>
<tr>
<td>HDL-C (mmol/L)</td>
<td>1.35 ± 0.28</td>
<td>1.25 ± 0.15</td>
<td>1.36 ± 0.24</td>
<td>0.014</td>
<td>1.28 ± 0.23</td>
<td>1.51 ± 0.32</td>
<td>0.0009</td>
</tr>
<tr>
<td>HDL-D (nm)</td>
<td>9.95 ± 0.23</td>
<td>9.99 ± 0.15</td>
<td>10.04 ± 0.21</td>
<td>0.170</td>
<td>9.98 ± 0.15</td>
<td>10.08 ± 0.22</td>
<td>0.0046</td>
</tr>
<tr>
<td>HDL2.C (mmol/L)</td>
<td>0.84 ± 0.27</td>
<td>0.77 ± 0.15</td>
<td>0.86 ± 0.22</td>
<td>0.036</td>
<td>0.81 ± 0.19</td>
<td>0.99 ± 0.29</td>
<td>0.073</td>
</tr>
<tr>
<td>HDL3.C (mmol/L)</td>
<td>0.51 ± 0.04</td>
<td>0.48 ± 0.03</td>
<td>0.50 ± 0.04</td>
<td>0.031</td>
<td>0.48 ± 0.05</td>
<td>0.52 ± 0.05</td>
<td>3.14 x 10^-5</td>
</tr>
<tr>
<td>ApoA1 (g/L)</td>
<td>1.57 ± 0.16</td>
<td>1.44 ± 0.10</td>
<td>1.53 ± 0.15</td>
<td>0.0096</td>
<td>1.44 ± 0.15</td>
<td>1.63 ± 0.19</td>
<td>4.89 x 10^-6</td>
</tr>
<tr>
<td>ApoB (g/L)</td>
<td>0.98 ± 0.21</td>
<td>0.87 ± 0.15</td>
<td>0.89 ± 0.17</td>
<td>0.364</td>
<td>0.80 ± 0.15</td>
<td>0.88 ± 0.22</td>
<td>0.025</td>
</tr>
<tr>
<td>ApoB/ApoA1</td>
<td>0.63 ± 0.15</td>
<td>0.61 ± 0.10</td>
<td>0.59 ± 0.12</td>
<td>0.180</td>
<td>0.56 ± 0.10</td>
<td>0.55 ± 0.16</td>
<td>0.370</td>
</tr>
</tbody>
</table>

Data are expressed as mean ± SD. D represents diameter of particles. C represents the content of cholesterol within each lipoprotein particle. p values are calculated by paired t tests comparing lipid levels at randomization and 1 year follow-up. False discovery rate (FDR) corrected significance p-value < 0.02.

HDL, high-density lipoprotein; LDL, low-density lipoprotein; VLDL, very-LDL.
controls as well as lower levels of HDL3-C, S- and M-HDL particles. These changes may reflect a nutrient-derived attenuation of reverse cholesterol transportation aided by HDL particles, but future studies are needed to clarify this potential mechanism.

Participants in this study were obese, but otherwise healthy and severe dyslipidemia, was not registered in this population. Therefore, it can be speculated that greater changes in lipid profiles, including levels of apoB, may be found in populations with more severe degrees of dyslipidemia or known CVD. LDL cholesterol is routinely measured in clinical practice, but as mentioned, LDL measurements have certain disadvantages. The LDL cholesterol concentration does not contain information on other atherogenic lipoproteins, and some patients will develop atherosclerotic disease despite LDL within the normal range (46). Hence, it might be clinically relevant to include measurements of apoB when monitoring patients with dyslipidemia and CVD to provide a more accurate lipid profile for risk development of a CVD event.

In conclusion, acute weight loss in individuals with obesity improves the atherogenic lipid profiles, but the changes revert towards screening levels despite weight maintenance. However, with liraglutide treatment, the lowering of apoB levels is maintained, reflecting a change in LDL metabolism, which may contribute to a decreased CVD risk.

Conflicts of Interest Statement

S. M. and J. J. H. have performed consultant services for Novo Nordisk. S. S. T. and T. H. hold stocks in Novo Nordisk. L. E., J. L., N. W. A., Y. M., E. W. I., P. F., A. E. J. and H. V. have no relevant conflict of interest for this study.

Author Contributions

J. J. H., S. S. T. and S. M. planned the study. J. L. and E. W. I. conducted the clinical tests. Y. M and L. E. performed the statistical tests. J. L., L. E., Y. M., N. W. A. and S. S. T intrepreted data. L. E. and J. L. wrote the first draft. All authors participated in editing the manuscript.

Acknowledgements

This work was supported by a research grant from the Danish Diabetes Academy (by the Novo Nordisk Foundation), the Danish Council for Independent Research The Lundbeck Foundation, The P Carl Petersen Foundation, Tripartite Immunometabolism Consortium [TrIC]- Novo Nordisk Foundation; Grant number NNF15CC0018486 and the University Investment Capital (UNIK): Food, Fitness and Pharma for Health and Disease from the Danish Ministry of Science. Cambridge Weight Plan products were donated from Cambridge Weight Plan. Funding parties were not involved in the study design, conduction of the study, data analysis or approval of manuscript. We thank the dieticians Jane Hjort and Stine Larsen, Hvidovre Hospital.

Funding

The study incl. purchase of Victoza pens (liraglutide) was supported by funding from The Danish Research Council for Health and Disease (ref. no.: 11-107683) and the University Investment Capital (UNIK): Food, Fitness and Pharma for Health and Disease from the Danish Ministry of Science, Technology and Innovation. Victoza (Liraglutide injection pens) was paid with funding obtained from The Danish Research Council for Health and Disease (ref. no.: 11-107683). Salaries were funded by The Lundbeck Foundation, The P Carl Petersen Foundation and the Danish Diabetes Academy (funded by the Novo Nordisk Foundation). Cambridge Weight Plan products were donated from Cambridge Weight Plan. The funding sponsors were not involved in the study design, conduction of the study, data analysis or approval of manuscript.

References


Supporting Information

Additional Supporting Information may be found online in the supporting information tab for this article.

Table S1. Metabolite concentrations during acute weight loss intervention.
Table S2. Metabolite concentrations during weight maintenance for 52 weeks.